UCLA: Advances in Radiation Therapy for Prostate & Other Cancers

UCLA researchers present innovative radiation therapy findings at ASTRO 2025, including targeted therapy, SBRT, and imaging advancements for prostate, head, and neck cancers. #radiationtherapy #cancerresearch

Dr. Beth Neilsen, a former radiation previous resident at Local, will discuss will certainly go over searchings for study that research tumors assessed lumps with clients cancer that returned after radiation therapy. These understandings dropped light on why some prostate cancers stand up to radiation and may assist future therapy approaches.

Targeted Therapy for Recurrent Prostate Cancer

At this year’s scientific meeting, Dr. Amar Kishan, executive vice chair of radiation oncology at UCLA and co-director of the Cancer Molecular Imaging, Nanotechnology and Theranostics Program at the UCLA Health Jonsson Comprehensive Cancer cells Facility, will certainly offer searchings for from the LUNAR medical trial (Abstract 3), which looks at including 177Lutetium-PSMA, a targeted contaminated therapy, as a treatment given prior to ablative radiotherapy for guys with frequent prostate cancer. The results will be highlighted throughout a public speaking on Sunday, Sept. 28 at 1:10 pm PDT in the San Francisco Ballroom and becomes part of the ASTRO information instruction on Monday, Sept. 29 at 11am PDT.

Postoperative SBRT for Head and Neck Cancers

Dr. Miriam Lane, a radiation oncology homeowner at UCLA, will offer searchings for from a study assessing postoperative SBRT for clients with recently identified or recurring head and neck cancer cells. The research study will certainly be provided on Monday, Sept. 29 at 10:45 am PDT in Hall F.

MRI-Guided Radiation for Prostate Cancer

Dr. Travis Courtney, co-chief resident in the division of radiation oncology at UCLA, is offering study contrasting 2 MRI-guided forms of targeted radiation treatment for prostate cancer cells. The study looked at typical high-dose MRI-guided stereotactic body radiotherapy (MRgSBRT) versus an adaptive “dose-painted” strategy that increases radiation to leading lump areas while lowering the dosage to bordering cells. The findings recommend that raising dosage to specific lump areas may not decrease side results and highlight the demand for more research study as the test continues to enlist people.

Dr. Jesus Juarez Casillas, co-chief citizen in the department of radiation oncology at UCLA, will offer findings from the Knife stage II professional trial, which reviewed stereotactic body radiation treatment (SBRT) in males at threat of prostate cancer cells returning after surgical treatment. Dr. Travis Courtney, co-chief local in the department of radiation oncology at UCLA, is offering research study contrasting two MRI-guided types of targeted radiation treatment for prostate cancer cells. Dr. Jonathan Massachi, a radiation oncology resident at UCLA, will review searchings for from the MIRAGE test that looked at sexual function in males obtaining SBRT for prostate cancer, contrasting standard CT-guided SBRT with MRI-guided SBRT. Dr. Miriam Lane, a radiation oncology citizen at UCLA, will provide findings from a study evaluating postoperative SBRT for individuals with freshly diagnosed or frequent head and neck cancer. The research will be provided on Monday, Sept. 29 at 10:45 am PDT in Hall F.

Sexual Function After Prostate SBRT

Dr. Jonathan Massachi, a radiation oncology resident at UCLA, will certainly go over findings from the MIRAGE trial that checked out sex-related function in men receiving SBRT for prostate cancer, contrasting basic CT-guided SBRT with MRI-guided SBRT. Despite making use of MRI advice to minimize radiation exposure to essential nerves and blood vessels, nearly one-third of males in both teams experienced a considerable decline in sex-related function 2 years after therapy. Factors such as hormonal agent treatment, pelvic radiation, and baseline sexual function were connected to these adjustments. The searchings for recommend that while MRI-guided SBRT can reduce some radiation exposure, additional methods, like vessel-sparing methods, might be required to better maintain sex-related feature in guys going through prostate cancer cells therapy. The research study, led by Kishan, will be presented on Monday, Sept. 29 at 8:20 am PDT in Space 307/308.

5DCT Imaging for Lung Tumors

Dr. Daniel Low, professor and vice chair of medical physics study and development in the department of radiation oncology at UCLA will certainly report findings from the very first big study of 5DCT, a new CT imaging technique created to enhance scans for clients with lung tumors that breathe off-and-on. In a study of 108 people, 5DCT permitted medical professionals to a lot more precisely specify growth size and activity, supporting better radiation planning.

While we just use edited and approved content for Azthena
responses, it may once in a while provide wrong responses.
Please verify any information provided with the related vendors or
authors. We do not give medical advice, if you look for
clinical info you need to always consult a clinical
specialist prior to acting on any information given.

UCLA researches featured at this year’s ASTRO meeting deal exciting new understandings into arising radiation therapies and imaging innovations, indicating innovative methods to make cancer cells therapy more secure, much more accurate, and a lot more reliable. These discussions highlight the collaborative efforts of our researchers, doctors, and students, and mirror UCLA’s long-lasting management and dedication to advancing cancer treatment.”

Physicians and scientists from the UCLA Health And Wellness Jonsson Comprehensive Cancer cells Facility will share the most up to date research and medical test results at the 2025 American Culture for Radiation Oncology (ASTRO) Yearly Fulfilling, including researches on targeted contaminated therapy for persistent prostate cancer, new techniques to stereotactic body radiation for prostate and head and neck cancers, breakthroughs in MRI- and 5DCT-guided imaging for a lot more accurate treatments, and advancements in patient-focused cancer education and learning.

News-Medical. Web gives this clinical information solution in accordance
with these conditions.
Please note that clinical details discovered
on this site is created to support, not to change the relationship
between patient and physician/doctor and the clinical advice they may give.

In Addition, Dr. Drew Moghanaki, principal of thoracic oncology in UCLA’s department of radiation oncology, has been called a 2025 fellow of ASTRO. The acknowledgment is awarded every year to medical professionals, physicists, and scientists in honor of their phenomenal success and lasting contributions to the society, cancer cells study, education and learning, individual treatment, and the field of radiation oncology, highlighting job that breakthroughs the important function of radiation treatment in cancer cells treatment.

Digital Tools for Cancer Education

Dr. Beth Neilsen, a former radiation oncology resident at UCLA, will discuss will certainly talk about searchings for study that research tumors examined growths with clients cancer that returned after radiation therapy.

Dr. Jesus Juarez Casillas, co-chief local in the division of radiation oncology at UCLA, will certainly present searchings for from the knife stage II professional trial, which examined stereotactic body radiation therapy (SBRT) in men at risk of prostate cancer cells returning after surgical treatment. After 4 years, 62% of people had no indicators of cancer cells returning, local recurrences were rare, and results contrasted positively with standard radiation techniques. The research study, led by Kishan, will certainly exist on Sunday, Sept. 28 at 5:05 pm PDT in Space 24.

Dr. Trudy Wu, assistant teacher of radiation oncology at UCLA, will moderate a panel exploring exactly how digital tools are changing cancer cells education and learning. Panelists Dr. David Grew, Dr. Hyunsoo No, and client advocate Jill Feldman will share techniques for making complex cancer details, such as therapy options, side impacts, and prognosis, more accessible and easy to understand.